Contingent Value Rights - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Jul. 28, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Fair value of contingent value rights		$ 923		$ 1,076
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jul. 28, 2020
Upfront cash for acquisition	$ 43,000
Additional aggregate payments		$ 13,500		$ 13,500
Business acquisition, description		As of March 31, 2022 and December 31, 2021, the holders of the CVRs are entitled to receive potential future cash payments of up to $13.5 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (ii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.
Gain (loss) recorded as other income (expense), net resulting from the change in fair value of CVRs		$ 200	$ 500
Agreement 1 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates		4,500
Net sales from related parties		35,000
Agreement 2 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates		9,000
Net sales from related parties		$ 55,000